Update: The Ventana's PD-L1 (SP142) Assay was classified as a complementary diagnostic for atezolizumab when the drug was granted accelerated approval from the US Food and Drug Administration in 2016. It has since become a companion diagnostic for the drug in urothelial and other cancers.